CTOs on the Move

Total e-Medical

www.totalemedical.com

 
Total e-Medical is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Boca Raton, FL. To find more information about Total e-Medical, please visit www.totalemedical.com
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

National HealthCare Services

National HealthCare Services is a Long Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Microliter

Microliter is a Cutchogue, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Homecare America

Homecare America is a Jupiter, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Continucare Corporation

Continucare Corporation is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Continucare Corporation is based in Miami, FL. You can find more information on Continucare Corporation at www.continucare.com

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.